ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

19 сен 2023 16:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

06 сен 2023 16:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

08 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

01 авг 2023 16:00:00 Источник Nasdaq GlobeNewswire

Acumen Announces Pricing of Upsized $130 Million Public Offering

18 июл 2023 22:31:16 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

17 июл 2023 16:53:41 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease

17 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

16 июл 2023 03:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023

13 июн 2023 11:10:48 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

09 май 2023 07:00:03 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

04 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

02 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

28 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

27 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

22 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

20 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

08 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

13 фев 2023 08:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

04 янв 2023 08:00:02 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

14 ноя 2022 16:01:01 Источник Nasdaq GlobeNewswire